ASSOCIATION OF POLYMORPHISM IN TICAM1 GENE WITH PROTECTION TO MODERATE/SEVERE COVID-19

Resumen

Clinical outcomes of Covid-19 have shown variability between individuals and populations.
TICAM1 gene encodes the TRIFF protein, essential in the antiviral response, then the purpose
of the study was to assess the effect of the polymorphism (rs2292151) G>A of TICAM1 gene
on the severity of COVID-19 in individuals from the northern region of Paraná. A case-control
study was performed, including patients, 100 mild and 50 moderate/severe Covid-19 cases,
classified according to the WHO, by Hospital Paraná, Maringá, Brazil. The exclusion criteria
used were: patients with heart disease, liver disease, other respiratory diseases, HIV, and cancer.
The (rs2292151) G>A polymorphism was genotyped by qPCR and statistical analysis was
performed using logistic regression in the SNPStats software. The genotype distribution was
according to the expected in the Hardy-Weinberg equilibrium. There was an association
between the A/A genotype in a codominant model with protection against the severity of the
disease (OR=0.14, 95% CI 0.03.-0.75, P = 0.01). The frequency of genotype A/A was 12% in
mild cases and 4% in serious cases; the G/A was 44% in mild cases and 30% in serious cases,
and the G/G was 44% in mild cases and 66% in serious cases. We can conclude that the A/A
genotype (in a codominant genetic model) of the polymorphism (rs2292151) G>A was
associated with a protection factor for moderate/severe Covid-19 in this population, however,
the genotype determination should be done in a high number of patients.